NEUROCRINE BIOSCIENCES INC Operating Expenses
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Expenses of $1.03 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-02-11
- NEUROCRINE BIOSCIENCES INC operating expenses for the quarter ending 2020-12-31 was $176.10M, a 9.83% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC operating expenses for the quarter ending 2020-09-30 was $302.80M, a 129.39% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating expenses for the quarter ending 2020-06-30 was $225.80M, a 51.44% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC operating expenses for the quarter ending 2020-03-31 was $178.20M, a 25.56% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC operating expenses for fiscal 2021 was $1.03B, a 16.77% increase from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC operating expenses for fiscal 2020 was $882.90M, a 23.34% increase from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC operating expenses for fiscal 2019 was $715.80M, a 72.73% increase from fiscal 2018.
- NEUROCRINE BIOSCIENCES INC operating expenses for fiscal 2018 was $414.40M, a 41.44% increase from fiscal 2017.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $1.03B 10-K · filed 2022-02-11 | |||||
| 2020-12-31 | $176.10M 10-K · filed 2021-02-05 | $478.90M derived: sum of 2 quarters · filed 2021-02-05 | $704.70M derived: sum of 3 quarters · filed 2021-02-05 | $882.90M 10-K · filed 2022-02-11 | ||
| 2020-09-30 | $302.80M 10-K · filed 2021-02-05 | $528.60M derived: sum of 2 quarters · filed 2021-02-05 | $706.80M derived: sum of 3 quarters · filed 2021-02-05 | $902.10M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2020-06-30 | $225.80M 10-K · filed 2021-02-05 | $404.00M derived: sum of 2 quarters · filed 2021-02-05 | $599.30M derived: sum of 3 quarters · filed 2021-02-05 | $731.30M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2020-03-31 | $178.20M 10-K · filed 2021-02-05 | $373.50M derived: sum of 2 quarters · filed 2021-02-05 | $505.50M derived: sum of 3 quarters · filed 2021-02-05 | $654.60M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2019-12-31 | $195.30M 10-K · filed 2021-02-05 | $195.29M 10-K · filed 2020-02-07 | $327.30M derived: sum of 2 quarters · filed 2021-02-05 | $476.40M derived: sum of 3 quarters · filed 2021-02-05 | $715.80M 10-K · filed 2022-02-11 | $715.80M 10-K · filed 2020-02-07 |
| 2019-09-30 | $132.00M 10-K · filed 2021-02-05 | $132.00M 10-Q · filed 2019-11-04 | $281.10M derived: sum of 2 quarters · filed 2021-02-05 | $520.51M 10-Q · filed 2019-11-04 | $630.12M derived: sum of 4 quarters · filed 2021-02-05 | |
| 2019-06-30 | $149.10M 10-K · filed 2021-02-05 | $149.12M 10-Q · filed 2019-07-29 | $388.52M 10-Q · filed 2019-07-29 | $498.12M derived: sum of 3 quarters · filed 2021-02-05 | $595.55M derived: sum of 4 quarters · filed 2021-02-05 | |
| 2019-03-31 | $239.40M 10-K · filed 2021-02-05 | $349.02M derived: sum of 2 quarters · filed 2021-02-05 | $446.45M derived: sum of 3 quarters · filed 2021-02-05 | $545.21M derived: sum of 4 quarters · filed 2021-02-05 | ||
| 2018-12-31 | $109.62M 10-K · filed 2020-02-07 | $207.06M derived: sum of 2 quarters · filed 2020-02-07 | $305.81M derived: sum of 3 quarters · filed 2020-02-07 | $414.40M 10-K · filed 2021-02-05 | $414.35M 10-K · filed 2019-02-08 | |
| 2018-09-30 | $97.43M 10-K · filed 2020-02-07 | $196.19M derived: sum of 2 quarters · filed 2020-02-07 | $304.72M 10-Q · filed 2019-11-04 | $387.41M derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-06-30 | $98.76M 10-K · filed 2020-02-07 | $207.29M 10-Q · filed 2019-07-29 | $289.97M derived: sum of 3 quarters · filed 2020-02-07 | $356.74M derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-03-31 | $108.53M 10-K · filed 2020-02-07 | $191.22M derived: sum of 2 quarters · filed 2020-02-07 | $257.99M derived: sum of 3 quarters · filed 2020-02-07 | $321.59M derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2017-12-31 | $82.68M 10-K · filed 2019-02-08 | $149.45M derived: sum of 2 quarters · filed 2019-02-08 | $213.06M derived: sum of 3 quarters · filed 2019-02-08 | $292.99M 10-K · filed 2020-02-07 | ||
| 2017-09-30 | $66.77M 10-K · filed 2019-02-08 | $130.37M derived: sum of 2 quarters · filed 2019-02-08 | $210.30M 10-Q · filed 2018-11-05 | $256.56M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-06-30 | $63.60M 10-K · filed 2019-02-08 | $143.53M 10-Q · filed 2018-07-31 | $189.79M derived: sum of 3 quarters · filed 2019-02-08 | $228.22M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-03-31 | $79.93M 10-K · filed 2019-02-08 | $126.18M derived: sum of 2 quarters · filed 2019-02-08 | $164.62M derived: sum of 3 quarters · filed 2019-02-08 | $206.45M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2016-12-31 | $46.25M 10-K · filed 2018-02-13 | $84.69M derived: sum of 2 quarters · filed 2018-02-13 | $126.52M derived: sum of 3 quarters · filed 2018-02-13 | $162.37M 10-K · filed 2019-02-08 | ||
| 2016-09-30 | $38.44M 10-K · filed 2018-02-13 | $80.26M derived: sum of 2 quarters · filed 2018-02-13 | $116.12M 10-Q · filed 2017-11-01 | $146.87M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-06-30 | $41.83M 10-K · filed 2018-02-13 | $77.69M 10-Q · filed 2017-08-03 | $108.43M derived: sum of 3 quarters · filed 2018-02-13 | $144.28M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-03-31 | $35.86M 10-K · filed 2018-02-13 | $66.61M derived: sum of 2 quarters · filed 2018-02-13 | $102.45M derived: sum of 3 quarters · filed 2018-02-13 | $127.77M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2015-12-31 | $30.75M 10-K · filed 2017-02-14 | $66.59M derived: sum of 2 quarters · filed 2017-02-14 | $91.91M derived: sum of 3 quarters · filed 2017-02-14 | $113.97M 10-K · filed 2018-02-13 | ||
| 2015-09-30 | $35.84M 10-K · filed 2017-02-14 | $61.17M derived: sum of 2 quarters · filed 2017-02-14 | $83.22M 10-Q · filed 2016-11-02 | $103.69M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2015-06-30 | $25.32M 10-K · filed 2017-02-14 | $47.38M 10-Q · filed 2016-08-03 | $67.85M derived: sum of 3 quarters · filed 2017-02-14 | $84.70M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2015-03-31 | $22.06M 10-K · filed 2017-02-14 | $42.52M derived: sum of 2 quarters · filed 2017-02-14 | $59.38M derived: sum of 3 quarters · filed 2017-02-14 | $73.74M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2014-12-31 | $20.47M 10-K · filed 2016-02-11 | $37.33M derived: sum of 2 quarters · filed 2016-02-11 | $51.69M derived: sum of 3 quarters · filed 2016-02-11 | $64.41M 10-K · filed 2017-02-14 | ||
| 2014-09-30 | $16.86M 10-K · filed 2016-02-11 | $31.22M derived: sum of 2 quarters · filed 2016-02-11 | $43.94M 10-Q · filed 2015-10-29 | $56.20M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-06-30 | $14.36M 10-K · filed 2016-02-11 | $27.09M 10-Q · filed 2015-07-29 | $39.35M derived: sum of 3 quarters · filed 2016-02-11 | $52.08M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-03-31 | $12.72M 10-K · filed 2016-02-11 | $24.98M derived: sum of 2 quarters · filed 2016-02-11 | $37.72M derived: sum of 3 quarters · filed 2016-02-11 | $51.62M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2013-12-31 | $12.26M 10-K · filed 2015-02-09 | $25.00M derived: sum of 2 quarters · filed 2015-02-09 | $38.89M derived: sum of 3 quarters · filed 2015-02-09 | $52.60M 10-K · filed 2016-02-11 | ||
| 2013-09-30 | $12.73M 10-K · filed 2015-02-09 | $26.63M derived: sum of 2 quarters · filed 2015-02-09 | $40.34M 10-Q · filed 2014-11-04 | $53.70M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2013-06-30 | $13.90M 10-K · filed 2015-02-09 | $27.60M 10-Q · filed 2014-08-06 | $40.97M derived: sum of 3 quarters · filed 2015-02-09 | $54.29M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2013-03-31 | $13.71M 10-K · filed 2015-02-09 | $27.07M derived: sum of 2 quarters · filed 2015-02-09 | $40.39M derived: sum of 3 quarters · filed 2015-02-09 | $52.34M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2012-12-31 | $13.37M 10-K · filed 2014-02-11 | $26.68M derived: sum of 2 quarters · filed 2014-02-11 | $38.63M derived: sum of 3 quarters · filed 2014-02-11 | $51.69M 10-K · filed 2015-02-09 | ||
| 2012-09-30 | $13.32M 10-K · filed 2014-02-11 | $25.27M derived: sum of 2 quarters · filed 2014-02-11 | $38.33M 10-Q · filed 2013-10-29 | $48.99M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-06-30 | $11.95M 10-K · filed 2014-02-11 | $25.01M 10-Q · filed 2013-07-26 | $35.67M derived: sum of 3 quarters · filed 2014-02-11 | $46.87M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-03-31 | $13.06M 10-K · filed 2014-02-11 | $23.72M derived: sum of 2 quarters · filed 2014-02-11 | $34.92M derived: sum of 3 quarters · filed 2014-02-11 | $45.98M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2011-12-31 | $10.66M 10-K · filed 2013-02-08 | $21.86M derived: sum of 2 quarters · filed 2013-02-08 | $32.92M derived: sum of 3 quarters · filed 2013-02-08 | $43.49M 10-K · filed 2014-02-11 | ||
| 2011-09-30 | $11.19M 10-K · filed 2013-02-08 | $22.25M derived: sum of 2 quarters · filed 2013-02-08 | $32.83M 10-Q · filed 2012-10-31 | $46.61M derived: sum of 4 quarters · filed 2013-02-08 | ||
| 2011-06-30 | $11.06M 10-K · filed 2013-02-08 | $21.63M 10-Q · filed 2012-07-31 | $35.42M derived: sum of 3 quarters · filed 2013-02-08 | $47.40M derived: sum of 4 quarters · filed 2013-02-08 | ||
| 2011-03-31 | $10.57M 10-K · filed 2013-02-08 | $24.36M derived: sum of 2 quarters · filed 2013-02-08 | $36.34M derived: sum of 3 quarters · filed 2013-02-08 | $46.87M derived: sum of 4 quarters · filed 2013-02-08 | ||
| 2010-12-31 | $13.79M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $25.77M derived: sum of 2 quarters · filed 2013-02-08 | $36.30M derived: sum of 3 quarters · filed 2013-02-08 | $47.22M 10-K · filed 2013-02-08 | ||
| 2010-09-30 | $11.98M 10-Q · filed 2011-10-31 | $22.52M derived: sum of 2 quarters · filed 2011-10-31 | $33.44M 10-Q · filed 2011-10-31 | |||
| 2010-06-30 | $10.53M 10-Q · filed 2011-07-29 | $21.45M 10-Q · filed 2011-07-29 | ||||
| 2009-12-31 | $56.62M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |